Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS) today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd., modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement. Under the amendment, monthly installment payments will now begin on April 1, 2026, with principal repayments following a defined schedule agreed between the Company and Yorkville. The core economic terms of the $6.0 million financing remain unchanged. Jupiter Neurosciences is a B2i Digital Featured Company. View the company profile at https://b2idigital.com/jupiter-neurosciences-1. The amendment relates solely to installment timing and application mechanics; it does not alter the underlying economic terms of the financing, nor does it introduce any new pricing provisions, reset features, or additional financing commitments. "This amendment reflects a deliberate and aligned decision between Jupiter and Yorkville," said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences. "Yorkville demonstrated its commitment to our long-term strategy by adjusting installment timing without changing pricing, maturity or other economic terms. That alignment enables us to remain focused on advancing our Phase II Parkinson's program while continuing to scale Nugevia™ and build commercial cash flow." In addition to advancing its neuroinflammation pipeline, the Company notes that it is generating revenue through Nugevia™, its patented JOTROL™-based resveratrol platform. Current ecommerce sales reflect repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. See the full news release at https://www.pressviewer.com/ViewEmail.asp?b=3018&id=383681&p=2423532&I=1447373-F8U6y4D6y3. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The Company's lead clinical program is advancing through a Phase IIa trial in Parkinson's disease. Jupiter is also commercializing Nugevia™, a consumer product built on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability. Jupiter's dual-path strategy combines clinical development with commercial revenue generation. The company is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com. Investor inquiries: [email protected]. Discover more emerging growth Featured Companies and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

$JUNS get ready! Happy Monday!! Let’s rock!!!!

$JUNS #News out!!/ Great companies! Check em out. #NYSE, #NASDAQ, #OTCMARKETS #DYAI #Dyadic #biotechnology #MWAI #MedwellAI #agelessbeauty #WTER Alkaline88 #LFEV - #life EV #radpowerbikes Rad Power Bikes #electricbike #BETRF #Betterlife #LSD #Biotech #VMAR Vision Marine Tech - #electricboat #VRME #VerifyMe®, #OpenWorld #Web3 #AUID #authID #Biometrics #CVM Cel-Sci #biotech Get some Dilligence here: https://youtube.com/@thebullrunshow?si=Ghp4pGMy74nfRSoS #AI #wallstreet #TheBullRunShow #Youtube #stockstowatch